Market Overview

UPDATE: Bank of America Initiates Questcor Pharmaceuticals with Buy on Favorable Fundamentals

Related QCOR
BioTime CEO Explains What Could Happen To Stem Cell Research And The Company Under A New Guard In Washington
Mallinckrodt Is No Valeant-Philidor Situation, Morgan Stanley Says

Bank of America initiated coverage on Questcor Pharmaceuticals (NASDAQ: QCOR) with a Buy rating and price objective of $60 a share.

Bank of America commented, "We believe QCOR has uniquely favorable fundamentals, due to 19 legacy indications for Acthar, orphan drug pricing, rapid revenue growth, low operating expenses, and high margin-driven share repurchases. However, Acthar has no patent protection and we believe the risk of generic competition (see below) will remain an overhang. In the intermediate term, we see upside to the shares as we expect revenue and earnings to be well ahead of expectations. Even based on consensus estimates, the stock is attractive on 2012 P/E and EV/sales metrics."

Questcor Pharmaceuticals closed at $45.48 on Thursday.

Latest Ratings for QCOR

May 2014MizuhoDowngradesBuyNeutral
May 2014PiperJaffrayDowngradesOverweightNeutral
Apr 2014JefferiesDowngradesBuyHold

View More Analyst Ratings for QCOR
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Pre-Market Outlook Analyst Ratings


Related Articles (QCOR)

View Comments and Join the Discussion!